

Technology Advisory Interests Register

Topic: encorafenib with binimetinib for treating BRAF V600E mutation-positive advanced non-small-cell lung cancer [ID6177]

Publication Date: TBC

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Kate Ren	TAC Committee Member	Direct- financial	I provided a training course on indirect treatment comparison for MSD's HTA statistics team. This is not related to any specific treatment or disease area. I also provided statistical methodology consultancy service to a possible comparator company Pfizer for an unrelated treatment in an unrelated disease area (Tofacitinib for Moderate-to-Severe Ulcerative Colitis).	11/04/2025 23/08/2025	It was agreed that Kate's declaration would not prevent them from participating in discussions on this appraisal
Elizabeth Thurgar	TAC Committee Member	Direct- financial	Elizabeth is currently working with Pfizer (not listed in the comparator companies) in NSCLC. In the past 12 months she has worked with BMS in an unrelated indication, myelodysplastic syndrome.	11/04/2025 19/08/2025	It was agreed that Elizabeth's declaration would not prevent them from participating in discussions on this appraisal
Stella O'Brien	TAC Committee Member	Indirect – Professional	Stella is an author/contributor for HTA NIHR136097 – “Treatments for metastatic non-small-cell lung cancer: a pathways pilot with systematic review, evidence	11/04/2025 19/08/2025	It was agreed that Stella's declaration would not prevent them from

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			synthesis, and economic model” for which she received no remuneration. This is due for publication after we've responded to some minor review points.		participating in discussions on this appraisal
Satish Venkateshan	TAC Committee Member	Direct- financial	Regeneron has cemiplimab licensed for a variety of indications including some non-small cell lung cancer indications. Regeneron also has other medicines currently in development for lung cancer indications. Satish works for Regeneron, pharmaceuticals/biotech company. He also owns shares in the company and have stock options.	22/04/2025 21/08/2025	It was agreed that Satish's declaration would prevent them from participating in discussions on this appraisal
Mike Chambers	TAC Committee Member	Financial	I have participated in an advisory panel for Pfizer (possible comparator company) in an unrelated disease area: prostate cancer	19/08/2025	It was agreed that Mike's declaration would not prevent them from participating in discussions on this appraisal
Toby Talbot	Clinical Expert	Direct- financial	Toby has received two payments from Pierre-Fabre for advisory board activity directly relating to encorafenib. He has received travel grants, speaker fees and advisory board activity fees from Bristol Myers	18/10/2024 09/09/2025	It was agreed that Toby's declaration would not prevent them from providing expert advice to the committee

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			Squibb, Regeneron, Pierre Fabre, Daiichi Sankyo and Merck Sharp & Dohme. He has also received a speaker fee for speaking at a promotional meeting regarding encorafenib and binimetinib in melanoma in March 2025.		
Thomas Newson-Davis	Clinical Expert	Direct- financial	Thomas has received payments from BMS, Boehringer Ingelheim, MSD and Roche for advisory boards, conference attendance and speaking engagements, from Merck for advisory boards and from Novartis for advisory boards and speaking engagements. He has been a member of an Independent Data Monitoring Committee for Roche. He is a member of a Clinical Trial Steering Committee for MSD. He is the Chair of the BTOG Steering Committee. He is also a member of a Clinical Trial Steering Committee for AstraZeneca	23/10/2024	It was agreed that Thomas's declaration would not prevent them from providing expert advice to the committee